The OncoDaily Grand Rounds at ESMO 2026: Sarcoma Edition will take place on October 23, 2026, from 1:00 PM to 4:00 PM, at the Novotel Madrid Feria and Airport in Madrid, Spain, bringing together leading specialists for a dedicated scientific discussion on developments in sarcoma research and clinical management.
Organized during the ESMO 2026 Congress, the meeting will provide an opportunity for experts to examine emerging evidence, discuss current challenges in sarcoma treatment, and consider the implications of recent research for clinical practice.
Following the successful Sarcoma Grand Rounds held during ASCO 2026, OncoDaily is continuing the series in Madrid, with the support of Agenus, Deciphera Pharmaceuticals, PharmaMar, and the Sarcoma Foundation of America.
Sarcoma at the Center of Scientific Discussion
Sarcomas represent a diverse group of malignancies arising from mesenchymal tissues, with considerable differences in their biological characteristics, clinical behavior, and response to treatment. Their rarity and heterogeneity present important challenges for diagnosis, clinical research, and therapeutic decision-making.
Advances in molecular characterization, targeted therapies, systemic treatment, and multidisciplinary management have contributed to a more individualized approach to sarcoma care. Nevertheless, several important questions remain regarding optimal treatment selection, management of advanced disease, and the integration of emerging evidence into routine clinical practice.
The OncoDaily Grand Rounds at ESMO 2026: Sarcoma Edition will provide a dedicated setting for examining these developments and discussing their potential implications for patients with sarcoma.
The meeting will be co-chaired by Professor Robin Jones and Professor Javier Martín-Broto, bringing together international expertise for scientific exchange focused on current evidence, clinical challenges, and future directions in the field.
From ASCO to ESMO: Continuing the Sarcoma Grand Rounds
The upcoming meeting builds on the Sarcoma Grand Rounds organized by OncoDaily during ASCO 2026, extending the scientific discussion to another major international oncology congress.
The ESMO edition will continue this initiative by bringing specialists together to review developments in sarcoma research and consider how new findings may influence treatment strategies.
Through its Grand Rounds series, OncoDaily provides a forum for scientific discussion among oncology professionals, connecting clinical experience with emerging research and encouraging the exchange of perspectives across institutions and countries.
The Madrid meeting will continue this approach, with particular attention to the evolving treatment landscape and the clinical questions that remain central to sarcoma management.
Agenus and Deciphera Pharmaceuticals Join as Enhanced Partners
Agenus and Deciphera Pharmaceuticals will support the OncoDaily Grand Rounds at ESMO 2026: Sarcoma Edition as Enhanced Partners, contributing to the organization of this dedicated scientific meeting.
Agenus is a biotechnology company engaged in the development of cancer immunotherapies, with research focused on approaches intended to improve antitumor immune responses. Its participation as an Enhanced Partner reflects the involvement of the biotechnology sector in supporting scientific exchange within oncology.
Deciphera Pharmaceuticals is an oncology-focused pharmaceutical company with experience in the development of targeted treatments, including therapies relevant to gastrointestinal stromal tumors (GIST), a distinct category of soft tissue sarcoma.
Its participation is particularly relevant to the broader discussion of molecularly targeted treatment strategies and the role of precision medicine in the management of selected sarcoma subtypes.
As Enhanced Partners, both companies will support an event dedicated to examining scientific developments and facilitating discussion among specialists working in sarcoma research and clinical care.
PharmaMar Supports the Meeting as Foundational Partner
PharmaMar will participate in the OncoDaily Grand Rounds at ESMO 2026: Sarcoma Edition as a Foundational Partner.
The company has an established presence in oncology drug development, with particular experience in marine-derived anticancer compounds and therapies used in the management of soft tissue sarcomas.
PharmaMar’s work in oncology includes the development of trabectedin, a treatment used in certain settings for patients with advanced soft tissue sarcoma.
Its involvement in the Madrid meeting brings an additional industry perspective to an event focused on the evolving therapeutic landscape of sarcoma, where continued research remains important for expanding treatment options and addressing unmet clinical needs.
As a Foundational Partner, PharmaMar will support the scientific meeting and its objective of facilitating discussion on developments relevant to sarcoma care.
Sarcoma Foundation of America: Bringing Patient Advocacy into the Discussion
Alongside the pharmaceutical and biotechnology partners, the Sarcoma Foundation of America (SFA) will participate as the Strategic Patient Advocacy Partner of the OncoDaily Grand Rounds at ESMO 2026: Sarcoma Edition.
The Sarcoma Foundation of America is a patient advocacy organization dedicated to advancing sarcoma research, increasing awareness, and supporting individuals and families affected by the disease.
Patient advocacy organizations have an important role in rare cancers, where limited awareness, diagnostic delays, and difficulties accessing specialized care can create additional challenges for patients.
The involvement of SFA adds a patient advocacy perspective to the meeting and recognizes the importance of considering patient needs alongside scientific and therapeutic developments.
Its participation also reflects the value of collaboration between clinicians, researchers, industry representatives, and patient organizations in addressing the challenges associated with rare malignancies.
A Shared Commitment to Progress in Sarcoma Oncology
The participation of Agenus, Deciphera Pharmaceuticals, PharmaMar, and the Sarcoma Foundation of America reflects the different contributions of biotechnology, pharmaceutical research, and patient advocacy to the broader sarcoma community.
Although each organization has a distinct role and area of expertise, their support of the OncoDaily Grand Rounds contributes to an international meeting dedicated to scientific exchange and professional collaboration.
For rare and heterogeneous malignancies such as sarcomas, communication between specialists and institutions remains particularly important. Differences in disease subtypes, treatment pathways, and available evidence make multidisciplinary expertise and international cooperation essential components of high-quality care.
The upcoming Grand Rounds will provide an opportunity to continue these discussions during one of the major oncology meetings of the year.
Join OncoDaily Grand Rounds at ESMO 2026 in Madrid
The OncoDaily Grand Rounds at ESMO 2026: Sarcoma Edition will take place on Friday, October 23, 2026, from 1:00 PM to 4:00 PM, at the Novotel Madrid Feria and Airport, located at C. de Ámsterdam, 3, Barajas, 28042 Madrid, Spain, approximately two minutes’ walk from IFEMA Madrid.
Co-chaired by Professor Robin Jones and Professor Javier Martín-Broto, the event will bring together leading experts to discuss developments shaping sarcoma research and clinical practice.
With the support of its Enhanced Partners, Foundational Partner, and Strategic Patient Advocacy Partner, OncoDaily will continue its Sarcoma Grand Rounds series, providing a dedicated forum for scientific discussion during ESMO 2026.
Oncology professionals attending ESMO 2026 are invited to join the meeting in Madrid and take part in the continuing discussion on advances in sarcoma care.
